Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2012 | |
| Cash Flows From Operating Activities | |
| Net Income | -3,140 |
| Depreciation Amortization | 5 |
| Other Working Capital | -140 |
| Other Operating Activity | 205 |
| Operating Cash Flow | $-3,070 |
| Cash Flows From Investing Activities | |
| PPE Investments | -30 |
| Investing Cash Flow | $-30 |
| Cash Flows From Financing Activities | |
| Other Financing Activity | 3,680 |
| Financing Cash Flow | $3,680 |
| Beginning Cash Position | 140 |
| End Cash Position | 710 |
| Net Cash Flow | $570 |
| Free Cash Flow | |
| Operating Cash Flow | -3,070 |
| Free Cash Flow | -3,070 |